Tenderwize
Zurück zur Suche

Formoterol and Aclidinium Bromide Medicines

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Feb 27, 2027 · 185 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Formoterol und Aclidiniumbromid (ATC: R03AL05)

55/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

55 / 100

Komplexität

42 / 100

Risikofaktoren

Structured data says electronic submission is not allowed, while the XML text says documents may also be sent by email...

The structured deadline is 2027-02-27T23:00:00Z, while the XML notice shows an end date of 2027-02-28.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Conclusion of non-exclusive rebate/discount agreements for finished medicinal products with Formoterol and Aclidinium bromide (ATC R03AL05).
  • Open-house model with equal access conditions for all eligible pharmaceutical companies or groups of companies.
Vollständige Zusammenfassung anzeigen

This is an open-house style German medicines supply notice for non-exclusive discount agreements on products with the active ingredient combination Formoterol and Aclidinium bromide (ATC R03AL05). The lead buyer is AOK Sachsen-Anhalt. The notice states that any suitable pharmaceutical company may join under the same conditions, with no individual negotiations and no exclusivity. The contract can start from 2025-05-01 and ends no later than 2027-04-30. Electronic submission is not allowed, but the XML text mentions a possible emailed PDF with qualified electronic signature, creating an inconsistency that should be clarified.

Risiken

Structured data says electronic submission is not allowed, while the XML text says documents may also be sent by email...

The structured deadline is 2027-02-27T23:00:00Z, while the XML notice shows an end date of 2027-02-28.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The notice indicates that the contract is only available to suitable and interested pharmaceutical companies or groups of pharmaceutical companies.

Administrative

  • Interested pharmaceutical companies must request the participation documents and the contract from the contact address.
  • Participation documents must be completed in full and signed.

Zuschlagskriterien

Lot 1

No explicit award criteria stated; open-house access on equal terms.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Formoterol and Aclidinium Bromide Medicines

Non-exclusive discount agreements for finished medicinal products containing the active ingredient combination Formoterol and Aclidinium bromide (ATC R03AL05). The lot follows an open-house model with identical terms for all eligible applicants and no individual contract negotiations. The lot information comes from structured data and XML text. The contract may start from 2025-05-01 and lasts up to 24 months, ending on 2027-04-30 regardless of start date.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Zuschlagskriterien

No explicit award criteria stated; open-house access on equal terms.

Frist

Deadline Feb 27, 2027

Vergabedetails

Veröffentlichungsdatum
19 Mar 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
180026-2025

Dokumente (1)

Ähnliche Ausschreibungen